¼¼ºê¶õ½ºº´¿ø ¿°Áõ¼º ÀåÁúȯ ±âÃÊ Áß°³ ¿¬±¸ ½ÉÆ÷Áö¾ö : 2023-06-11
±³À°ÀÏÀÚ : 2023-06-11
±³À°Àå¼Ò : ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ 1Ãþ À¯ÀÏÇÑ È¦
±³À°ÁÖÁ¦ : ¿°Áõ¼º ÀåÁúȯ ±âÃÊ Áß°³ ¿¬±¸ ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ¼¼ºê¶õ½ºº´¿ø
½ÃÇà±â°ü(ÁöºÎ/°ú) : ³»°ú
´ã´çÀÚ : ±èÇýºó
¿¬¶ôó : 02-2228-2264
À̸ÞÀÏ : hb14@yuhs.ac
±³À°Á¾·ù : ÀÇÇб³À°, ±âŸ
Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 4 ½Ã°£ 15ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í ±³À°Á¾·ù : ±âÃʱ³À°
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 06¿ù 11ÀÏ À¯ÀÏÇÑ È¦ 09:00~09:05 Àλ縻 õÀçÈñ(¿¬¼¼ÀÇ´ë ¼Òȱ⳻°ú(IBD¼¾ÅÍ ¼ÒÀå))
±³À°½Ã°£ 06¿ù 11ÀÏ À¯ÀÏÇÑ È¦ 09:05~09:30 anti-IL23 antibodies / JAK inhibitors: recent clinical updates ¿¹º´´ö(¿ï»êÀÇ´ë ¼Òȱ⳻°ú)
±³À°½Ã°£ 06¿ù 11ÀÏ À¯ÀÏÇÑ È¦ 09:30~09:55 Impact of Th17 cells on IBD pathogenesis ±è½Â¿ø(¿¬¼¼ÀÇ´ë ÷´ÜÀÇ°úÇб³À°¿¬±¸´Ü)
±³À°½Ã°£ 06¿ù 11ÀÏ À¯ÀÏÇÑ È¦ 09:55~10:20 From Colitis to Cancer: Targeting Pathogenic Type-17 Immune Function ÀÌÁØ¿ë(¿¬¼¼ÀÇ´ë ¹Ì»ý¹°Çб³½Ç)
±³À°½Ã°£ 06¿ù 11ÀÏ À¯ÀÏÇÑ È¦ 10:20~10:30 Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function ¹ÚÀ̽½(¿¬¼¼ÀÇ´ë ¼Òȱ⳻°ú)
±³À°½Ã°£ 06¿ù 11ÀÏ À¯ÀÏÇÑ È¦ 10:30~10:55 The efficacy and safety of FMT in pediatric patients with IBD ¹Ú¼Ò¿ø(¿¬¼¼ÀÇ´ë ¼Ò¾Æ¼Òȱ⿵¾ç°ú)
±³À°½Ã°£ 06¿ù 11ÀÏ À¯ÀÏÇÑ È¦ 10:55~11:20 Probiotics in IBD: Atypical E. coli as a therapeutic modality ¹ÚÁöÇý(¿¬¼¼ÀÇ´ë ¼Òȱ⳻°ú)
±³À°½Ã°£ 06¿ù 11ÀÏ À¯ÀÏÇÑ È¦ 11:20~11:45 Potential role of the intestinal microbiota in IBD ÀºÃ¢¼ö(ÇѾçÀÇ´ë ¼Òȱ⳻°ú)
±³À°½Ã°£ 06¿ù 11ÀÏ À¯ÀÏÇÑ È¦ 11:45~11:55 Colitis-resistant probiotics: New strain of B. longum resistant to hydrogen peroxide in IBD ±èÁöÇü(¿¬¼¼ÀÇ´ë ¼Òȱ⳻°ú)
ÈÞ½Ä 06¿ù 11ÀÏ 11:55~13:00 Á¡½É½Ä»ç ()
±³À°½Ã°£ 06¿ù 11ÀÏ À¯ÀÏÇÑ È¦ 13:00~13:25 Parkinson¡¯s disease and inflammatory bowel diseases ÀÌÈ£¼ö(¿ï»êÀÇ´ë »ýÈÇкÐÀÚ»ý¹°Çб³½Ç)
±³À°½Ã°£ 06¿ù 11ÀÏ À¯ÀÏÇÑ È¦ 13:25~13:50 Development of anti-fibrotic agent for intestinal fibrosis in Crohn À¯ÁØȯ(Â÷ÀÇ°ú´ë ¼Òȱ⳻°ú)
±³À°½Ã°£ 06¿ù 11ÀÏ À¯ÀÏÇÑ È¦ 13:50~14:15 Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases. Çöâ±â(Çѵ¿´ë »ý¸í°úÇкÎ)
±³À°½Ã°£ 06¿ù 11ÀÏ À¯ÀÏÇÑ È¦ 14:15~14:25 Hepatic steatosis but not fibrosis is independently associated with poor outcomes in patients with inflammatory bowel disease ÇöÇý°æ(¿¬¼¼ÀÇ´ë ¼Òȱ⳻°ú)